Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Bilateral Wrist Septic Arthritis Caused by Group B β-Hemolytic Streptococcus: A Case Report.

Cureus·2026
Same author

Sex-Based Disparities in Health Care Access and Utilization Among Patients With Atrial Fibrillation.

JAMA network open·2026
Same author

PR Interval Alternans and the Mystery of Inverse Decremental Conduction.

JACC. Case reports·2026
Same author

When QTc Shrinks After Rhythm Conversion.

JACC. Case reports·2026
Same author

Patient health or corporate profits-Shouldn't the former come first?

The American journal of medicine·2026
Same author

Brain Abscess Arising From Pansinusitis in an Immunocompetent Young Adult: A Diagnostic Challenge.

Cureus·2026

関連する実験動画

Updated: Jun 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

ドローン,ドローン,ドローン

Chinmay Patel1, Gan-Xin Yan, Peter R Kowey

  • 1Main Line Health Heart Center and Lankenau Hospital, Wynnewood, PA 19096, USA.

Circulation
|August 19, 2009
PubMed
まとめ
この要約は機械生成です。

アミオダロンの派生体であるドロネダロンは,心房細動の患者でシヌスリズムを効果的に維持します. 死亡率を減らす一方で,その安全性プロフィールは,特に重度の心不全の症例では,慎重に検討する必要があります.

さらに関連する動画

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

関連する実験動画

Last Updated: Jun 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

科学分野:

  • 心臓病学 心臓病学
  • 薬理学 薬理学とは

背景:

  • アミオダロンは心房細動に有効ですが,重大な副作用があります.
  • ドロネダロンは,アミオダロンの非オジンの誘導体であり,これらの問題を緩和するために開発されました.
  • 両薬とも複数のイオン電流を標的にし,抗アドレナジック作用を有する.

研究 の 目的:

  • 動脈動管理におけるドロネドロンの安全性と有効性を検討する.
  • ドロネドロンのプロフィールをアミオダロンと比較し,心臓外効果に焦点を当てました.

主な方法:

  • 動脈動におけるドロネドロンの臨床試験データのレビュー.
  • 薬理動力学および薬理動力学的性質の分析.
  • 安全性と有効性のエンドポイントの評価.

主要な成果:

  • ドロネダロンは,副鼻腔リズムを維持し,心室回転率を制御する効果を示した.
  • 高リスクの心房細動患者の死亡率と罹患率を低減することが示されました.
  • 重度の心不全の患者における安全性については懸念がある.

結論:

  • ドロネダロンは,心房細動に対する治療の選択肢を提供し,アミオダロンと比較して潜在的に改善された副作用プロファイルと有効性のバランスをとります.
  • 患者の慎重な選択が不可欠であり,特に重度の心不全での使用を避ける必要があります.
  • さらなる研究は,長期的な安全性と最適な患者集団を明確にすることができます.